According to authors, magnetic resonance imaging (MRI) should be used when incomplete signs of the rare complication are presented to help guide the skin biopsy.
A case report of a patient with eosinophilic faciitis (EF), or Shulman syndrome, as a complication of chronic graft-versus-host-disease (cGVHD) underscores the importance of magnetic resonance imaging (MRI) as a tool to guide decision-making in similar cases.
According to the authors of the case report, MRI should be leveraged in the case of incomplete signs of the rare complication to help guide the skin biopsy, as MRI can help facilitate a rapid diagnosis and initiation of treatment.
The authors describe the case as unusual, with the patient presenting with EF in the absence of hypereosinophilia after receiving an allogenic hematopoietic stem cell transplant (ASCT) to treat his relapsed/refractory multiple myeloma.
“The incidence of EF in patients who have undergone ASCT presenting as cGVHD is rare,” emphasized the researchers. “To our knowledge, only one case of a patient with multiple myeloma has been reported.”
While not required for diagnosis, between 60% and 90% of cases present with eosinophilia. The majority (90%) of these cases also have skin involvement with an evolutive natural history. In the present case, the patient showed similar manifestations, exhibiting pain, swelling, induration, and edema.
The patient, a White male aged 46 years, also presented with hepatic dysfunction, which preceded the clinical signs, as well as normal eosinophil counts and incomplete clinical signs.
Based on body MRI results—which showed heightened signal intensity in short tau inversion recovery sequences in the superficial and deep fasciae—the patient received a skin-to-muscle biopsy of the left thigh. The biopsy confirmed fasciitis and edema with rare eosinophil infiltration.
“MRI is an important diagnostic and prognostic tool of EF, typically showing increased signal intensity within the fascia,” wrote the researchers. “It is the ideal imaging modality both for selecting the best site for biopsy and monitoring the course of EF following initiation of treatment.”
They continued, “In our case, MRI was crucial in enabling an early diagnosis in combination with other data (clinical, biological and anatomical pathology). Although not strictly required for diagnosis, MRI results appear to be required as part of the initial assessment of EF.”
Following the skin-to-muscle biopsy, liver biopsy confirmed the patient had accompanying cGVHD with fibrosis, and inflammatory infiltrate featuring lymphocytes and eosinophil granulocytes without apoptotic bodies.
Reference
Chalopin T, Vallet N, Morel M, et al. Eosinophilic fasciitis (Shulman syndrome), a rare entity and diagnostic challenge, as a manifestation of severe chronic graft-versus-host disease: a case report. J Med Case Rep. Published online March 15, 2021. doi:10.1186/s13256-021-02735-3
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More